尼可地尔联合辅酶Q10治疗慢性心力衰竭的临床效果

摘要
图/表
参考文献(21)
相关文章 (15)

全文: PDF (597 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨尼可地尔联合辅酶Q10治疗慢性心力衰竭的应用效果。方法选取2018年10月至2020年11月北京王府中西医结合医院收治的80例慢性心力衰竭患者作为研究对象，采用随机数字表法将患者分为对照组和试验组，每组40例。两组均进行心力衰竭的常规治疗，对照组给予辅酶Q10，试验组在对照组基础上给予尼可地尔。治疗4个月后，比较两组患者的6 min步行距离（6MWD）、静息心率（HR）、左心室射血分数（LVEF）、超氧化物歧化酶（SOD）、C-反应蛋白（CRP）、肿瘤坏死因子（TNF-α）、血清脑钠肽（BNP）的变化及不良反应发生情况。结果治疗前两组的6MWD、HR、LVEF比较，差异无统计学意义（P＞0.05）；治疗后试验组的6MWD长于对照组，HR低于对照组，LVEF高于对照组，差异有统计学意义（P＜0.05）。治疗前两组的SOD、TNF-α、CRP、BNP比较，差异无统计学意义（P＞0.05）；治疗后试验组SOD水平高于对照组，TNF-α、CRP、BNP水平低于对照组，差异有统计学意义（P＜0.05）。治疗后试验组患者心功能分级优于对照组，治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。两组不良反应总发生率比较，差异无统计学意义（P＞0.05）。结论尼可地尔联合辅酶Q10可以降低慢性心力衰竭患者血清中炎症细胞因子水平改善氧化应激状态，治疗效果较好具有较高的临床应用价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	耿二冬

关键词 ：尼可地尔, 辅酶Q10, 心力衰竭, 炎症因子, 氧化应激

Abstract：Objective To investigate the effect of Nicorandil combined with Coenzyme Q10 in patients with chronic heart failure. Methods A total of 80 patients with chronic heart failure admitted to Beijing Wangfu Hospital of Integrated Traditional Chinese and Western Medicine from October 2018 to November 2020 were selected as the research subjects. The patients were divided into control group and experimental group by random number table method, with 40 patients in each group. Both groups received conventional treatment of heart failure, the control group was given Coenzyme Q10, the experimental group was given Nicorandil based on the control group. After 4 months of treatment, the changes of 6 min walking distance (6MWD), resting heart rate (HR), left ventricular ejection fraction (LVEF), superoxide dismutase (SOD), C-reactive protein (CRP), tumor necrosis factor (TNF-α), serum brain natriuretic peptide (BNP) and the incidence of adverse reactions were compared between two groups. Results There were no significant differences in 6MWD, HR and LVEF between the two groups before treatment (P>0.05). After treatment, 6MWD of the experimental group was longer than that of the control group, HR was lower than that of the control group, and LVEF was higher than that of the control group, with statistically significant differences (P<0.05). There were no significant differences in SOD, TNF-α, CRP and BNP between the two groups before treatment (P>0.05). After treatment, SOD level in experimental group was higher than control group, TNF-α, CRP and BNP levels were lower than control group, the differences were statistically significant (P<0.05). After treatment, the grading of cardiac function in experimental group was better than that in control group, the total effective rate was higher than that of control group, the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion Nicorandil combined with Coenzyme Q10 can reduce the level of serum inflammatory cytokines and improve the state of oxidative stress in patients with chronic heart failure.

Key words： Nicorandil Coenzyme Q10 Heart failure Inflammatory factors Oxidative stress

引用本文:

耿二冬. 尼可地尔联合辅酶Q10治疗慢性心力衰竭的临床效果[J]. 中国当代医药, 2022, 29(19): 65-69.
GENG Erdong. Clinical effect of Nicorandil combined with Coenzyme Q10 in the treatment of chronic heart failure. 中国当代医药, 2022, 29(19): 65-69.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I19/65

[6]	Edelmann F，Knosalla C，M■rike K，et al.Chronic Heart Failure[J].Dtsch Arztebl Int，2018，115（8）：124-130.
[11]	赖凌燕，蒋辉.尼可地尔治疗稳定型心绞痛患者的疗效及药学分析[J].中国医药科学，2021，11（22）：69-72.
[12]	张远恒，陈绪江.尼可地尔治疗冠状动脉慢血流的临床效果[J].中国当代医药，2020，27（16）：47-50.
[1]	Muneer K，Nair A.Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease-Demystifying controversies[J].Indian Heart J，2017， 69（3）：371-374.
[3]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98-122.
[4]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[2]	Mortensen AL，Rosenfeldt F，Filipiak KJ.Effect of coenzyme Q10 in Europeans with chronic heart failure：A sub-group analysis of the Q-SYMBIO randomized double-blind trial[J].Cardiol J，2019，26（2）：147-156.
[5]	Okazaki H，Shirakabe A，Hata N，et al.Prognostic benefit of acute heart failure associated with atherosclerosis：the importance of prehospital medication in patients with severely decompensated acute heart failure[J].Heart Vessels，2018，33（12）：1496-1504.
[7]	Singhania G，Ejaz AA，McCullough PA，et al.Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization-a Review[J].Rev Cardiovasc Med，2019，20（3）：111-120.
[8]	Zozina VI，Covantev S，Goroshko OA，et al.Coenzyme Q10 in Cardiovascular and Metabolic Diseases：Current State of the Problem[J].Curr Cardiol Rev，2018，14（3）：164-174.
[9]	Xing Y，Liu C，Wang H，et al.Protective Effects of Nicorandil on Cardiac Function and Left Ventricular Remodeling in a Rat Model of Ischemic Heart Failure[J].Arch Med Res，2018，49（8）：583-587.
[10]	Harada K，Yamamoto T，Okumura T，et al.Intravenous nicorandil for treatment of the urgent phase acute heart failure syndromes：A randomized，controlled trial[J].Eur Heart J Acute Cardiovasc Care，2017，6（4）：329-338.
[13]	赵静，葛晓丽，靳丽君，等.尼可地尔联合辅酶Q10治疗慢性心力衰竭的疗效及对血清炎性因子及氧化应激水平的影响[J].中西医结合心脑血管病杂志，2019，17（6）：892-895.
[14]	Kiyuna LA，Albuquerque RPE，Chen CH，et al.Targeting mitochondrial dysfunction and oxidative stress in heart failure：Challenges and opportunities[J].Free Radic Biol Med，2018，129：155-168.
[15]	Kalter-Leibovici O，Freimark D，Freedman LS，et al.Disease management in the treatment of patients with chronic heart failure who have universal access to health care：a randomized controlled trial[J].BMC Med，2017，15（1）：90.
[16]	Prabhu SD，Frangogiannis NG.The Biological Basis for Cardiac Repair After Myocardial Infarction：From Inflammation to Fibrosis[J].Circ Res，2016，119（1）：91-112.
[17]	Waldman M，Cohen K，Yadin D，et al.Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ′SIRT1 and PGC-1α′[J].Cardiovasc Diabetol，2018，17（1）：111.
[18]	Alawieh H，Chemaly TE，Alam S，et al.Towards Point-of-Care Heart Failure Diagnostic Platforms：BNP and NT-proBNP Biosensors[J].Sensors （Basel），2019，19（22）：5003.
[19]	黄冬梅，黄刚，余冬梅，等.血清指标联合超声检查指标对慢性心力衰竭的诊断价值分析[J].实用心脑肺血管病杂志，2021，29（11）：16-20.
[20]	陈蓉，郭俊芳，尹春阳，等.血浆 B 型钠尿肽水平对慢性心力衰竭的早期诊断价值研究[J].中国全科医学，2019， 22（S2）：50-52.
[21]	Kuster N ，Huet F，Dupuy AM，et al.Multimarker approach including CRP，sST2 and GDF-15 for prognostic stratification in stable heart failure[J].ESC Heart Fail，2020，7（5）：2230-2239.